Image

U.S. Tuberous Sclerosis Drugs Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

U.S. Tuberous Sclerosis Drugs Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Feb 2023
  • Country Level
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

U.S. Tuberous Sclerosis Drugs Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 237.20 USD Million
Diagram Market Size (Forecast Year) USD 1,250.70 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

U.S. Tuberous Sclerosis Drugs Market, By Gene (TSC2, TSC1), Site (Brain, Kidney, Skin, Heart, Lungs, Others), Drug Class (mTOR inhibitors, Anti-Convulsants, Cannabidiol or Epidiolex, Others), Drug Type (Branded, Generics), Population Type (Children, Adults), Route of Administration (Oral, Parenteral, Others), End User (Hospitals, Specialty Clinics, Academic & Research Institutes and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.

U.S. Tuberous Sclerosis Drugs Market Analysis and Size

The U.S. tuberous sclerosis drugs market is increasing significantly due to factors such as FDA approval of new drugs for the treatment of tuberous sclerosis. In 3 in every 4 cases, the genetic fault occurs in people no affected family members with this disease. Tuberous sclerosis causes mild disease in which individuals are left untreated in adulthood or it can cause major risks that can impact quality of life or the disorder small red spots appear between the ages of 3 and 5 years, mostly on the face and appear in a butterfly pattern.   

Data Bridge Market Research analyses a growth rate in the tuberous sclerosis drugs market in the forecast period 2023-2030. The expected CAGR of tuberous sclerosis drugs market is tend to be around 23.10% in the mentioned forecast period. The market value is USD 237.2 million in 2022, and it would grow upto USD 1250.7 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

U.S. Tuberous Sclerosis Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Gene (TSC2, TSC1), Site (Brain, Kidney, Skin, Heart, Lungs, Others), Drug Class (mTOR inhibitors, Anti-Convulsants, Cannabidiol or Epidiolex, Others), Drug Type (Branded, Generics), Population Type (Children, Adults), Route of Administration (Oral, Parenteral, Others), End User (Hospitals, Specialty Clinics, Academic & Research Institutes and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

Market Players Covered

Sanofi (France), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Amgen inc. (U.S.), Lilly (U.S.), AstraZeneca (U.K.), AbbVie Inc (U.S.), Johnson & Johnson Private Limited (U.S.), LEO Pharma A/S (Denmark), Merck & Co., Inc (U.S.), Bausch Health Companies Inc (Canada) and Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), Par Pharmaceutical (U.S.), Dr Reddy’s Laboratories Ltd (India), Jazz Pharmaceuticals, Inc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Viatris Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), VistaPharm, Inc. (U.S.)

Market Opportunities

  • Growing product launches by organizations
  • Increasing demand of mTOR inhibitors

Market Definition

Tuberous sclerosis is a type sporadic genetic, chronic disorder. The disorder is related with the formation of benign (non-cancerous) tumors in numerous organ of the body. The tumors are termed hamartomas, which is tumor-like propagated growth that consist of cells usually found in the area where the hamartoma formation occurs. The signs and symptoms of this disorder can vary person to person, and also among members of the same family, which is hereditary.

U.S. Tuberous Sclerosis Drugs Market Dynamics

Drivers

  • Increasing prevalence of tuberous sclerosis

Tuberous sclerosis is a type of rare genetic disorder that affects mostly around 1 in 6,000 newborns in the U.S. Around 40,000 to 80,000 people in the U.S. have tuberous sclerosis. The occurrence in Europe is expected to be around 1 in 25,000 to 1 in 11,300. Males and females are largely affected in equal numbers and the disorder occurs in all races and ethnic groups. Thus, this increasing inicidence demands a high amount of drugs which boost the market's growth.

  • Growing demand of diagnostic options

There are varied diagnostic options for tuberous sclerosis that boost the demand of the market. Molecular genetic testing can help in confirming a diagnosis of tuberous sclerosis. A number of tests can be used to help obtain a diagnosis of tuberous sclerosis or to evaluate or establish the extent of the disorder in an individual. Such tests include scanning and magnetic resonance imaging (MRI), computerized tomography (CT) to assess the brain for the wide presence of tumors or other brain involvement. Furthermore, tests such as an echocardiogram and an electrocardiogram (EKG) can be widely used to assess the heart for the presence of a rhabdomyoma. Thus, this boost the market growth.

Opportunities

  • Growing product launches by organizations

There has been an increasing number of product launches that are helpful in developing the market growth. Two drugs have been approved by the U.S. Food and Drug Administration for treating seizures associated with tuberous sclerosis. Also, in 2018, FDA approved Afinitor (everolimus) used for the treatment of seizures in pediatric and adult patients aged 2 years and above with tuberous sclerosis, and Epidiolex (cannabidiol) for patients one year and above in 2020. Thus, these product launches are boosting the growth of the market.

  • Increasing demand of mTOR inhibitors

Individuals under mTOR inhibitors for internal tumors may witness improvement in skin lesions. Topical formulations of mTOR inhibitors have shown great improvement in treating facial angiofibromas. For instance, the FDA approved mTOR inhibitors' use to treat lung complications such as Lymphangioleiomyomatosis (LAM) in individuals with tuberous sclerosis in 2015. Lymphangioleiomyomatosis occurs frequently in young women of childbearing age, therefore scientists have expected that female hormones such as estrogen play a major role i​​​​​​​n the development of the disorder. Thus, this rising adoption of mTOR inhibitors help in market growth.

Restraints/Challenges

  • High cost of drugs

Many drugs are associated with tuberous sclerosis such as conventional, anticonvulsants drugs, anti-seizure medication and numerous methods of rehabilitative and behavioral therapy. Majority of these treatment methods cost high. These drugs process causes the increased rate of cost. Thus, these factors restrict the market growth.

This tuberous sclerosis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tuberous sclerosis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

U.S. Tuberous Sclerosis Drugs Market Scope

The tuberous sclerosis drugs market is segmented on the basis of gene, site, drug class, drugs type, population type, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Gene

  • TSC2
  • TSC1

Site

  • Brain
  • Kidney
  • Skin
  • Heart
  • Lungs
  • Others

Drug Class

  • mTOR inhibitors
  • Anti-Convulsants
  • Cannabidiol or Epidiolex
  • Others

Drug Type

  • Branded
  • Generics

Population Type

  • Children
  • Adults

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Specialty Clinics
  • Academic & Research Institutes
  • Others

Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Competitive Landscape and U.S. Tuberous Sclerosis Drugs Market Share Analysis

The tuberous sclerosis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to tuberous sclerosis drugs market.

Key players operating in the tuberous sclerosis drugs market include:

  • Sanofi (France)
  • Novartis AG (Switzerland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Pfizer Inc. (U.S.)
  • Sanofi (France)
  • Amgen inc. (U.S.)
  • Lilly (U.S.)
  • AstraZeneca (U.K.)
  • AbbVie Inc (U.S.)
  • Johnson & Johnson Private Limited (U.S.)
  • LEO Pharma A/S (Denmark)
  • Merck & Co., Inc (U.S.)
  • Bausch Health Companies Inc (Canada)
  • Bristol-Myers Squibb Company (U.S.)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Par Pharmaceutical (U.S.)
  • Dr Reddy’s Laboratories Ltd (India)
  • Jazz Pharmaceuticals, Inc (U.K.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Viatris Inc. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • VistaPharm, Inc. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The U.S. Tuberous Sclerosis Drugs Market size will be worth USD 1250.7 million by 2030.
The U.S. Tuberous Sclerosis Drugs Market growth rate is 23.10% by 2030.
Increasing prevalence of tuberous sclerosis and Growing demand of diagnostic options are the growth drivers of the U.S. Tuberous Sclerosis Drugs Market.
The gene, site, drug class, drugs type, population type, route of administration, end user and distribution channel are the factors on which the U.S. Tuberous Sclerosis Drugs Market research is based.
The major companies in the U.S. Tuberous Sclerosis Drugs Market are Sanofi (France), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Amgen inc. (U.S.), Lilly (U.S.), AstraZeneca (U.K.), AbbVie Inc (U.S.), Johnson & Johnson Private Limited (U.S.), LEO Pharma A/S (Denmark), Merck & Co., Inc (U.S.), Bausch Health Companies Inc (Canada) and Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), Par Pharmaceutical (U.S.), Dr Reddy’s Laboratories Ltd (India), Jazz Pharmaceuticals, Inc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Viatris Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), VistaPharm, Inc. (U.S.).
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials